A propensity matched analysis of outcomes and long term survival in stented versus stentless valves

Blake N. Shultz 1*, Tomasz Timek 1, Alan T. Davis 2,3, John Heiser 1, Edward Murphy 1, Charles Willekes 1 and Robert Hooker 1

Abstract

Background: To compare the perioperative and long term survival after aortic valve replacement using stentless versus stented valves in a large cohort of patients grouped using propensity score matching.

Methods: From 1991 to 2012, 4,563 patients underwent aortic valve replacement with stentless and stented valves at our institution. Propensity score matching identified 444 pairs using 13 independent variables: incidence of operation, smoking status, renal failure, hypertension, diabetes, peripheral vascular disease, cerebrovascular disease, chronic lung disease, ejection fraction, gender, age, valve status, and use of coronary artery bypass graft. Data were collected from our Society of Thoracic Surgeons database and the Social Security Death Index. Groups were compared using univariate and Kaplan-Meier analysis.

Results: The two groups demonstrated no significant differences for the 13 matching variables and the majority of 30-day outcomes (p > 0.05). The stented valve group showed a higher incidence of postoperative bleeding (3.6% vs 1.1%, p = 0.015), but a lower incidence of stroke (0.9% vs. 2.9%, p = 0.028). One, five, and 10-year survival was 95.0, 80.7, and 52.8% for stented and 93.2, 80.5, and 51.3% for stentless valves. Overall survival did not differ significantly between the two groups (p = 0.641).

Conclusions: Stentless and stented valves had identical 30-day outcomes except for a higher postoperative incidence of bleeding and a lower incidence of stroke in the stented group. There was no significant difference in long term survival between valve types. Both valves may be used for aortic valve replacement with low morbidity and excellent long term survival.

Keywords: Aortic valve replacement, Stented bioprosthesis, Stentless bioprosthesis, Mortality, Morbidity

Background

Aortic valve replacement (AVR) is the standard of care for patients with significant aortic valve pathology [1]. Symptomatic aortic valve disease necessitating replacement may consist of stenosis, regurgitation or a mixed pattern. The stented valve has for decades been the most frequently employed valve in the aortic position when choosing a bioprosthesis. In the 1990s the stentless aortic valve was introduced in an effort to more closely model the hemodynamics of the native valve, possibly improving valve durability and clinical outcomes [2]. However, modern stented valves offer greatly improved hemodynamic characteristics [3]. Many studies have demonstrated excellent results with both stented [4–7], and stentless valves [3, 8, 9]. Comparative studies have suggested that stented and stentless valves have similar clinical outcomes and hemodynamic profiles such as left ventricular mass (LVM) regression, effective orifice area (EOA), and transvalvular gradients [8, 10–13].

Two studies have shown that stentless valves have improved survival rates and reduced incidence of adverse events [14, 15]. However, no large-scale studies directly comparing the clinical outcomes of these two valves are available in the literature. This study analyzes a single institution’s experience over the past two decades.
Stentless and stented valves were compared utilizing propensity matching analysis.

**Methods**

**Patients and data source**

Between 1991 and 2012, 4,563 patients underwent AVR utilizing a stented or stentless valve. Valves were all implanted according to manufacturer’s recommendations. All patients undergoing aortic valve replacement were prospectively entered into our institution’s Society of Thoracic Surgeons (STS) database. Data collected included patient demographics, comorbidities, operative characteristics, mortality, and 30-day morbidity. This study was approved by the Institutional Review Board (IRB) at Spectrum Health. Individual patient consent was waived.

**Operative technique**

Conventional cardiopulmonary bypass was performed utilizing roller head pumps and membrane oxygenators with cold/tepid blood cardioplegia. Stented valves were placed either intra-annular or supra-annular at the discretion of the surgeon using pledgeted sutures. Stented valves included Carpentier-Edwards Perimount (Edwards Life Sciences, Irvine, CA, USA), and Mosaic (Medtronic, Minneapolis, MN, USA). All stentless valves (Medtronic, Minneapolis, MN, USA) were sewn in via a subcoronary technique leaving the noncoronary sinus of the xenograft intact.

**Statistical analysis**

Categorical data are expressed as percentages and continuous variables are reported as the mean ± standard deviation (SD). Propensity matched pairs were identified by matching on the following 13 independent variables: incidence of operation, smoking status, renal failure, hypertension, diabetes, peripheral vascular disease, cerebrovascular disease, chronic lung disease, ejection fraction, gender, age, valve status, and whether or not a coronary artery bypass graft was used. Propensity matching of the subjects was performed using the method of Leuven and Sianesi [16]. The propensity matching was performed in three age cohorts: 1998–2002, 2003–2006, and 2007–2010. After matching in each of the three cohorts, the subjects were combined into two matched groups for comparison of the patients who received either the stentless or stented valves. The \( \chi^2 \) test and Fisher’s Exact Test were used for the univariate analyses of categorical data and the unpaired \( t \)-test for was used for the univariate analysis of continuous data. Due to the non-normal distribution of the data, the intensive care unit length of stay (ICU LOS) and hours on mechanical ventilation were log transformed prior to analysis, while the hospital length of stay was transformed using the inverse hyperbolic sine function. A Kaplan-Meier survival curve and a life table were constructed from patient mortality data. Significance was assessed at \( p < 0.05 \).

Stata version 14.2 [StataCorp, College Station, TX, USA] was used to perform the statistical analyses.

**Results**

The propensity matched balance between the two groups is shown in Table 1. The stentless valve group was slightly older, while the majority of patients were

| Variable                  | Stented (No. [%]) (n = 444) | Stentless (No. [%]) (n = 444) | \( P \)-Value |
|---------------------------|-----------------------------|--------------------------------|---------------|
| Age (y) \(^a\)            | 70.9 ± 11.8                 | 71.2 ± 10.8                    | 0.729         |
| Gender (male)             | 315 (71.0)                  | 318 (71.6)                     | 0.824         |
| Diabetes                  | 122 (27.5)                  | 126 (28.4)                     | 0.765         |
| Smoker                    | 168 (37.8)                  | 167 (37.6)                     | 0.945         |
| NYHA class                |                             |                                |               |
| I                         | 20 (6.9)                    | 23 (7.0)                       | 0.408         |
| II                        | 59 (20.3)                   | 77 (23.3)                      |               |
| III                       | 138 (47.6)                  | 165 (50.0)                     |               |
| IV                        | 73 (25.2)                   | 65 (19.7)                      |               |
| Operation Status          |                             |                                | 0.275         |
| First operation           | 391 (88.1)                  | 380 (85.6)                     |               |
| Reoperation               | 53 (11.9)                   | 64 (14.4)                      |               |
| Valve status              |                             |                                | 0.759         |
| Insufficient              | 115 (25.9)                  | 114 (25.7)                     |               |
| Mixed                     | 159 (38.3)                  | 150 (40.5)                     |               |
| Stenosis                  | 170 (35.8)                  | 180 (33.8)                     |               |
| Surgical procedure        |                             |                                | 0.419         |
| Isolated AVR              | 195 (43.9)                  | 207 (46.6)                     |               |
| AVR + CABG                | 249 (56.1)                  | 237 (53.4)                     |               |
| Hypertension              | 336 (75.7)                  | 337 (75.9)                     | 0.938         |
| Cerebrovascular disease   | 50 (11.3)                   | 56 (12.6)                      | 0.535         |
| Renal Failure             | 37 (8.3)                    | 39 (8.8)                       | 0.810         |
| Chronic Lung Disease      |                             |                                | 0.054         |
| None                      | 392 (88.3)                  | 386 (86.9)                     |               |
| Mild                      | 32 (7.2)                    | 35 (7.9)                       |               |
| Moderate                  | 14 (3.2)                    | 14 (3.2)                       |               |
| Severe                    | 6 (1.4)                     | 9 (2.0)                        |               |
| Ejection Fraction (%) \(^a\) | 53.8 ± 12.9                  | 53.7 ± 12.5                    | 0.930         |
| PVD                       | 52 (11.7)                   | 53 (11.9)                      | 0.917         |
| Year                      |                             |                                | >0.999        |
| 1998–2002                 | 114 (25.7)                  | 114 (25.7)                     |               |
| 2003–2006                 | 70 (15.8)                   | 70 (15.8)                      |               |
| 2007–2010                 | 260 (58.6)                  | 260 (58.6)                     |               |

\(^a\) NYHA New York Heart Association, AVR aortic valve repair, CABG, coronary artery bypass graft, PVD peripheral vascular disease

\(^a\) Data expressed as Mean ± SD
males in each cohort. Valve pathology was equally distributed with close to 35% in both groups being pure aortic stenosis (AS), with the remainder pure aortic insufficiency (AI) and mixed AS/AI. Seventy-six percent of patients in each group were hypertensive and although 38% of patients were smokers less than 6% in each cohort had moderate or severe lung disease. None of the variables between the two groups were significantly different.

Table 2 presents the distribution and analyses of 30-day postoperative outcomes within the stented and stentless groups. There were no significant differences found between the groups for postoperative mortality, atrial fibrillation, renal failure or ventilation time ($p > 0.05$). Bleeding that necessitated reoperation was significantly different between the two groups, occurring over three times more frequently in stented patients, compared to stentless patients. Conversely, almost three times as many people in the stentless group had a stroke, compared to the stented valve group (2.9% vs. 0.9%).

Table 3 shows survival rated at one, 5 and 10 years after valve implantation. The Kaplan-Meier survival curve is shown in Fig. 1. There is a slight divergence in the curves between 2 and 8 years with survival in the stented slightly better, however by log rank test there is no difference in survival ($p = 0.64$).

**Discussion**

AVR is a definitive treatment of aortic valve pathology with excellent survival and quality of life in patients. The positive clinical outcomes following AVR result from the relief of the pressure or volume overload on the heart. The choice of stentless or stented valve has been debated as to which most closely mimics the hemodynamics of the natural valve, a characteristic that potentially leads to improved clinical outcome. Prior literature has largely focused on a discussion of the hemodynamic profiles and performance results of each type of valve [4–13, 17]. Borger et al. retrospectively studied 737 patients who underwent AVR with stented and stentless valves [12].

**Table 2** 30-day postoperative outcomes and their distribution among the patients within the sample along with univariate analysis comparing the stentless vs. the stented group

| Variable                        | Stented [No. (%)] | Stentless [No. (%)] | P-Value |
|---------------------------------|-------------------|---------------------|---------|
| 30-day mortality                | 12 (2.7)          | 13 (2.9)            | 0.839   |
| Atrial fibrillation             | 127 (28.6)        | 136 (30.6)          | 0.508   |
| MI                              | 12 (2.7)          | 13 (2.9)            | 0.839   |
| Stroke                          | 4 (0.9)           | 13 (2.9)            | 0.028   |
| ICU admission                   | 155 (34.9)        | 144 (32.4)          | 0.435   |
| Readmission within 30 days      | 38 (8.8)          | 49 (11.2)           | 0.227   |
| Ventilation > 48 h              | 36 (8.1)          | 47 (10.6)           | 0.205   |
| Bleeding requiring reoperation  | 16 (3.6)          | 5 (1.1)             | 0.015   |
| Deep sternal infection          | 2 (0.5)           | 3 (0.7)             | >0.999  |
| Renal failure                   | 25 (5.6)          | 26 (6.0)            | 0.885   |
| Renal failure requiring dialysis| 14 (3.2)          | 13 (2.9)            | 0.845   |
| Length of hospital stay (d)$^b$ | 8.8 ± 7.2         | 8.8 ± 7.6           | 0.480   |
| Total ICU Stay (h)$^a$          | 63.7 ± 119.8      | 71.3 ± 126.0        | 0.095   |
| Ventilation Time (h)$^a$        | 28.0 ± 118.8      | 30.9 ± 91.4         | 0.578   |

*Data are expressed as % survival, with 95% confidence intervals in parentheses

**Table 3** One, five and ten-year survival rates within the stentless and stented groups, based on Kaplan-Meier analysis

| Survival | Stentless (n = 442) (%) | Stented (n = 442) (%) |
|----------|-------------------------|-----------------------|
| 1 year   | 93.2 (90.4–95.2)        | 95.0 (92.6–96.7)      |
| 5 years  | 80.5 (76.3–84.1)        | 80.7 (76.1–84.4)      |
| 10 years | 51.3 (43.5–58.5)        | 52.8 (44.8–60.1)      |

*Data are expressed as % survival, with 95% confidence intervals in parentheses

Fig. 1 Kaplan-Meier survival curve predicting long term survival of patients within the stented and stentless cohorts. Comparison using the log-rank test gave a $p$-value = 0.641
study found that stentless valves were an independent predictor of LVM regression, and that stentless valves were associated with improved midterm survival by univariate analysis. Smaller, randomized studies and meta-analyses have also compared stentless and stented valves. Most studies have found that stented and stentless valves have comparable clinical outcomes and hemodynamic profiles such as LVM regression, EOA and transvalvular gradients [8, 10–13]. However, alternate studies have suggested that stentless valves offer superior hemodynamic characteristics, although these improvements have not produced significant clinical outcome differences [4–7]. Stentless valves have been shown to produce greater improvement in left ventricular function in patients with a small aortic root or left ventricular impairment [3, 9, 10].

Our study has shown that both stentless and stented valves have excellent short-term survival. We had a 2.7% 30-day mortality in the stented group and a 2.9% mortality in the stentless group which was not statistically significant. Westaby et al. [14] also showed no difference in short-term mortality (before hospital discharge) between stentless and stented valves (8.0% vs 12.1%, \( p = 0.171 \)). However, Luciani et al. [15] showed higher early mortality (before hospital discharge) in stented versus stentless patients (6.2% vs 2.6%, \( p = 0.02 \)).

Long term survival in this cohort was excellent compared to other studies for both types of valves [14, 15]. Westaby et al. [14] showed improved survival in stentless patients at 5 years (84% vs 69%, \( p = 0.023 \)). Luciani et al. showed lower survival at 8 years in stented versus stentless patients (70 ± 5% vs 81 ± 3%, \( p = 0.01 \)) [15]. However, this may be due to bias favoring stented valves in older patients who have higher mortality rates than younger patients. Our propensity matched analysis controlled for some of the age bias by matching patients on age and other preoperative conditions. Our study also included a large number of patients (\( n = 444 \) of each valve type). Both prior studies had smaller cohort sizes relative to our study. Westaby et al. analyzed 160 stentless patients and 247 stented patients [14], while Luciani et al. analyzed 292 stented patients and 376 stentless patients [15].

We have also shown equipoise in most 30-day clinical outcomes between stented and stentless valves. As shown in Table 2, the incidence of atrial fibrillation, myocardial infarction, stroke, and renal failure as well as the length of hospital stay, ventilation time, and the total length of stay in the intensive care unit were statistically similar between the two valve types. While studies have found that stented and stentless valves have comparable clinical outcomes and hemodynamic profiles such as LVM regression, EOA and transvalvular gradients [8, 10–13], few studies have explicitly reported clinical outcome comparisons similar to our study.

We had a significantly higher incidence of bleeding requiring reoperation in stented valves. Contrary to our findings, prior studies have shown no significant difference in postoperative bleeding between stented and stentless valves [6, 14, 15]. Ali et al. found a 5% incidence of bleeding in a stented cohort vs. 6% in a stentless cohort [10]. We believe that most of the bleeding was coming from the aortotomy in the non-coronary sinus. The stentless valve is placed via a subcoronary technique that leaves the noncoronary sinus intact, and it may be easier to visualize the aortotomy and thus control any suture line bleeding.

The incidence of stroke was significantly higher in our stentless cohort. This finding is unexpected, and the difference between cohorts has not been shown in prior literature. While the incidence of stroke in our stentless group (2.9%) was similar to that shown in prior studies, the incidence in the stented cohort was lower (0.9%). Borger et al. found a 2% incidence of stroke in both groups [12]. Similarly, Cheng et al. showed a 3.6% incidence of stroke in the stentless group and 4.0% in the stented group [6]. It is possible that the long suture lines required for a stentless valve could lead to increased thrombus formation. Further study in a large cohort is necessary to elucidate the contributing factors to the increased incidence of stroke in stentless valve replacement.

Although prior studies have reached conflicting conclusions regarding the hemodynamic superiority of stentless versus stented valves, our results indicate that the 30-day clinical outcomes and long term survival of the two valves do not differ significantly regardless of any hemodynamic differences. However, there may be instances for which one valve may be preferred over the other. Multiple studies have suggested that stentless valves produce greater improvement in left ventricular function in patients with a small aortic root or left ventricular impairment [3, 9, 10]. Patients with calcification in the sinuses may not be able to undergo stentless implantation because of inability to perform the suture line under the coronaries.

Furthermore, a study by Kunadian et al. found that stentless valves require a more complex surgery with an average cross clamp time increase of 23 min and a 29 min longer bypass time [7]. Dunning et al. also found that the bypass and cross-clamp times were 10 min longer in stentless patients [4]. Our results failed to show any difference in outcomes despite the potentially longer cross clamp and bypass times. Finally, stentless valves are theorized to have a higher durability due to a lack of
stress at the stent site, as mentioned above [2]. However, Forcillo et al. have shown that the Carpentier-Edwards pericardial valve retains excellent durability and a low incidence of valve related complications after 25 years of experience with the valve [18]. This finding complements our study by suggesting that improvements in stented valves have led to similar durability and outcomes with stentless valves.

Limitations to this study include its retrospective nature. However, this is the largest propensity matched study in the literature comparing these bioprostheses and the large number of patients at risk increases the validity of the long term data. Another limitation to this study is the lack of hemodynamic performance data such as effective orifice area, peak/mean gradients, and LVM regression. While we have survival data we did not assess the quality of life in survivors. The causes of death, valve dynamics, and reoperations were also not able to be determined. Choice of valve was at the discretion of the surgeon and this bias could not be controlled. With any propensity matched study the two groups could have confounders that were not able to be identified by the 13 matching parameters chosen.

Conclusions

In conclusion, stented and stentless valves offer similar clinical outcomes and good long term survival. Stented valves exhibited a decrease in the incidence of stroke, and an increase in postoperative bleeding that required re-exploration three times as often as with stentless valves. Both valves are excellent choice for AVR and have equivalent outcomes.

Abbreviations

AI: Aortic insufficiency; AS: Aortic stenosis; AVR: Aortic valve replacement; CABG: Coronary artery bypass graft; EOA: Effective orifice area; ICU: Intensive care unit; IRB: Institutional review board; LOS: Length of stay; LVM: Left ventricular mass; MI: Myocardial infarction; NYHA: New York Heart Association; PVD: Peripheral vascular disease; SD: Standard deviation; STS: Society of Thoracic Surgeons

Acknowledgements

Not applicable.

Funding
Not applicable.

Availability of data and materials

The data sets supporting the conclusions of this article are available upon request to Dr. Hooker (email: dbobhooker@gmail.com) pending IRB approval.

Authors’ contributions

BS designed the study, helped to carry out statistical analysis and data collection, and drafted the manuscript. TT was involved in data collection and helped to draft the manuscript. AD helped to design the study, carried out statistical analysis and helped to draft the manuscript. RH conceived of the study, was involved in data collection and participated in drafting the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was reviewed and approved by the Spectrum Health Institutional Review Board and consent was waived due the retrospective nature of the study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Thoracic and Cardiovascular Surgery, Spectrum Health, Fred and Lena Meijer Heart and Vascular Institute, 100 Michigan St NE, Grand Rapids, MI 49503, USA. 2Grand Rapids Medical Education Partners, 945 Ottawa Ave NW, Grand Rapids, MI 49503, USA. 3Department of Surgery, Michigan State University, 15 Michigan St NE, Grand Rapids, MI 49503, USA.

Received: 26 January 2017 Accepted: 18 May 2017

Published online: 31 May 2017

References

1. Levy D, Garrison RJ, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham heart study. Ann Intern Med. 1989;110:101–7.
2. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg. 2005;79:1072–80.
3. Kunihara T, Schmidt K, Glombitza P, Dzindzibadze V, Lusisberg H, Schafers H. Root replacement using stentless valves in the small aortic root: a propensity score analysis. Ann Thorac Surg. 2006;82:1379–84.
4. Dunning J, Graham RJ, Thabryajah J, Stewart MJ, Kendall SWH, Hunter S. Stentless vs. stented aortic valve bioprostheses: a prospective randomized controlled trial. Eur Heart J. 2007;28:3269–74.
5. Jin XY, Peppper JR. Do stentless valves make a difference? Eur J Cardio- Thorac Surg. 2002;22:95–100.
6. Cheng D, Peppper J, Martin J, Stanbridge R, Ferdinand FD, Jamieson WRE, et al. Stentless versus stented bioprosthetic aortic valves: a systematic review and meta-analysis of controlled trials. Innovations. 2009;4:61–73.
7. Kunadian B, Vijayalakshmi K, Thornley AR, de Belder MA, Hunter S, Kendall S, et al. Meta-analysis of valve hemodynamics and left ventricular mass regression for stentless versus stented aortic valves. Ann Thorac Surg. 2007;84:73–9.
8. Ali A, Halstead JC, Cafferty F, Sharpley L, Rose F, Coulondr R, et al. Are stentless valves superior to modern stented valves?: A prospective randomized trial. Circulation. 2006;114:535–40.
9. Narang S, Satsangi DK, Banerjee A, Geelani MA. Stentless valves versus stented bioprostheses at the aortic position: midterm results. J Thorac Cardiovasc Surg. 2008;136:943–7.
10. Ali A, Halstead JC, Cafferty F, Sharpley L, Rose F, Lee E, et al. Early clinical and hemodynamic outcomes after stented and stentless aortic valve replacement: results from a randomized controlled trial. Ann Thorac Surg. 2007;83:2162–8.
11. Risteski PS, Martens S, Rouhollahpour A, Wimmer-Greinecker G, Moritz A, Doss M. Prospective randomized evaluation of stentless vs. stented aortic biologic prosthetic valves in the elderly at five years. Interact Cardiovasc Thorac Surg. 2009;8:449–53.
12. Borger MA, Carson SM, Ivanov J, Yao L, Scully HE, Feindel CM, et al. Stentless aortic valves Are hemodynamically superior to stented valves during Mid-term follow-Up: a large retrospective study. Ann Thorac Surg. 2005;80:2180–5.
13. Tamimi M, Bove T, Van Balleghem Y, Francois K, Taeymons Y, Van Nooten G. Stentless vs. Stented aortic valve replacement: left ventricular mass regression. Asian Cardiovasc Thorac Ann. 2005;13:112–8.
14. Westaby S, Horton M, Jin XY, Katsumata T, Ahmen O, Saito S, et al. Survival advantage of stentless aortic bioprostheses. Ann Thorac Surg. 2000;70:785–91.
15. Luciani GB, Casali G, Aurisma S, Santini F, Mazzucco A. Survival after stentless and stented xenograft aortic valve replacement: a concurrent, controlled trial. Ann Thorac Surg. 2002;74:1443–9.
16. Leuven E and Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. 2003. http://ideas.repec.org/c/boc/bocode/s432001.html. Accessed 22 Nov 2016.
17. Kobayashi J. Stentless aortic valve replacement: an update. Vasc Health Risk Management. 2011;7:345–51.
18. Forcillo J, Pellerin M, Perrault LP, Cartier R, Bouchard D, Demers P, Carrier M. Carpentier-Edwards pericardial valve in the aortic position: 25-years’ experience. Ann Thorac Surg. 2013;96:486–93.